Letters New oral anticoagulants

Safety of new oral anticoagulants in high risk patients

BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1861 (Published 06 March 2014) Cite this as: BMJ 2014;348:g1861
  1. Stephen Dalgleish, orthopaedic specialty registrar1
  1. 1NHS Tayside, Ninewells Hospital, Dundee, UK
  1. sdalgleish{at}nhs.net

Wallace and Davies are rightly worried by the lack of antidotes for new oral anticoagulants.1

Rivaroxaban, a direct factor Xa inhibitor, has been shown to be non-inferior to warfarin for the prevention of stroke and systemic emboli and is associated with comparable levels of bleeding.2 A small preliminary trial found that prothrombin complex concentrate …

View Full Text

Sign in

Log in through your institution

Subscribe